Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Philogen

Novartis building

Novartis gets speedy FDA review for midostaurin

Leukaemia treatment could become first targeted therapy for 25 years

Deal Watch October 2016

Allergan, Astellas, AstraZeneca, Boehringer Ingelheim and Eli Lilly feature in this month's pharma deals round-up

- PMLiVE

Pharma ‘could do better’ on social media engagement

Industry is comfortable with the tech but has work to do on its approach

Roche Basel Switzerland

AbbVie and Roche’s leukaemia drug venetoclax nears EU market

CHMP grants blood cancer treatment Venclyxto a conditional green light

National Institute for Health and Care Excellence NICE logo

AstraZeneca’s Forxiga set to be recommended by NICE

The type 2 diabetes ‘triple therapy’ is backed in draft guidance

AstraZeneca AZ

AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

Will receive $250m upfront with a further $1.27bn if drug reaches market in two indications

- PMLiVE

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Option to acquire the Austrian biotech after phase I trials remains open to Boehringer 

Deal Watch August 2016

Pfizer's hat trick as well as Sanofi, GlaxoSmithKline, Boehringer Ingelheim and more are featured in this month's round-up

- PMLiVE

Boehringer to add wireless data-collection to its Respimat inhaler

Joins forces with Qualcomm for COPD adherence collaboration

- PMLiVE

AbbVie’s venetoclax set for early access in UK

Drug for CLL patients included in EAMS by MHRA

- PMLiVE

Portola rejection hands advantage to Boehringer’s Pradaxa

FDA’s ruling on reversal agent for NOACs unexpected

Sanofi reception

EC approves Sanofi’s deal for Boehringer’s consumer business

Regulator passes the acquisition, subject to the French firm divesting some products

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links